DOB-CR

DOB-CR, or DOB/CR, an acronym of "DOB-conformationally restrained", also known as 7-bromo-5,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline, is a serotonin receptor modulator of the tetrahydroisoquinoline family. It is a cyclized phenethylamine and a derivative of the psychedelic drugs 2C-B and DOB in which the side chain has been cyclized with the benzene ring to form a tetrahydroisoquinoline ring system.

Pharmacology

The drug shows modest affinity for the serotonin 5-HT_2A receptor. Its affinity for the receptor was 242 to 250nM, which is about 6-fold lower than that of DOB. In contrast to DOB, DOB-CR completely failed to substitute for DOM in rodent drug discrimination tests. In addition, behavioral disruption occurred at higher doses. These findings suggest that DOB-CR would lack psychedelic effects in humans. The drug also failed to substitute for dextroamphetamine and MDMA in rodent drug discrimination tests, suggesting lack of stimulant or entactogenic effects as well. However, DOB-CR fully substituted for the structurally related selective α₂-adrenergic receptor ligand TDIQ, albeit with about 4-fold lower potency than TDIQ itself.

DOB-CR was first described in the scientific literature by Richard Glennon and colleagues by 1996.